Archive | March, 2015

Risk-Off for Biotech Trades… Update-2

4/1…at close ETF summary FBT at $116.87 down 1.15%, early support at $115. IBB at $340 touching bottom of upward channel, down 1%. XBI at $220.50 down 2.22%. At technical support. ETF leader with equal weight holdings in small and mid-caps. Another weak day for large caps ALXN, AMGN, BIIB, REGN. ———— Sideways Reversal Action […]

Continue Reading 0

Snap-Back Rally In Biotech-But Lagging Other Sectors

Global Rally Today But Healthcare Sector Lags A Bit DOW up 1.49% at 17,976 NASDAQ Up 1.15% at 4947 Healthcare up 0.93% We are in Day Two of the biotech rally that was sparked last Friday with the rumor supported by a Deutsche Bank analyst that Biomarin (BMRN) was a takeover target. The Company has […]

Continue Reading 0

Risk Off For Biotech Trades-BIIB, GILD, XBI…Update-2

Update 3/25 Mid-Day Trading NAZ Off 1.55% at 4917 “Bubble Talk” Picking Up-Mid Caps Vulnerable Biotech sector selling picked up today with a dramatic shift in sentiment exacerbated by an overall weak market. Also durable goods fell unexpectedly 1.4% in February indicating weak global growth.Technology was the weakest sector down 1.74% but the resilient healthcare […]

Continue Reading 0

NASDAQ Up -Biogen Idec Triggers Rally In Biotech

Biotech Stocks Are Soaring In Pre-Market Update at Mid Morning NASDAQ Up 39 to 5031  Healthcare Stocks Continue To Lead Biogen Idec (BIIB) Up 10% On Alzheimer Disease Phase 1 Data Encouraging Phase I data on aducanumab with 166 patients shows acceptable safety and amyloid plaque reduction prompts Company to skip early stage study and […]

Continue Reading 0

Biotech Bull Market-Trends to Watch #2: ETF Review-FBT XBI

Biotech and Healthcare ETFs Hit An All Time High–Another Rally Coming Today 3/20 M&A: Recent buy-outs of Cubist (CBST) for $9.5B and Pharmacyclics (PCYC) for $21B have raised the valuation bar. The healthcare sector remains strong and biopharmaceuticals are key to sales growth. Breakthroughs in genomics, targeted oncology and HCV drugs are blockbuster growth areas. […]

Continue Reading 0

Rayno Life Science Portfolios: AMGN,CLVS,ILMN,RGEN,TMO…Update 3/18

March 18-Stealth Rally With A Tempered Tape In Biotech NASDAQ up 0.92% Biotech stocks lagged the surprising FED rally today maybe because money was moving to other sectors.This bears close watching because only this week biotech stocks hit a new high.Money may be moving to lagging sectors like energy up 2.92% today. Nonetheless healthcare remained […]

Continue Reading 0

Rayno Life Sciences DX and Tools Update: 2015 Q1 Winners ALR,FMI,HOLX

Diagnostic Stocks rally with NASDAQ and Small Caps –IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after the JPMorgan Conference. Nonetheless the sector is attractive longer term […]

Continue Reading 0

What Sell-Off? Biotechs Cruise: CLVS, SGEN

Stocks in Sharp Sell-Off on Potential FED Rate Increase and Strong Dollar Deflation is Still Lurking S&P Down 1.7%, NASDAQ down 1.67% Biotech stocks avoided the severe sell-off today apparently immune to the strong dollar, flat earnings growth and FED interest rate concerns. Although life science stocks were mixed the bellwether ETFs held their ground: […]

Continue Reading 0

Biotechs Roaring Back: Do They Sense A Deal? Update -1 ABBV/PCYC

Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back  Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug Imbruvica for chronic lymphocytic leukemia hit $185M and is forecasted to hit the $1B […]

Continue Reading 0

Mid Cap Emerging Biopharmaceutical Companies: Valuations Do Matter for M&A

Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for  Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there” for the acquisition of Pharmacyclics (PCYC) by large healthcare companies such as Johnson and Johnson (JNJ) and […]

Continue Reading 0